IPP Bureau
Pfizer & BioNTech submits Phase 1 data to US FDA for booster dose Covid-19
By IPP Bureau - August 17, 2021
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
European Commission mandates InferVision AI to monitor Covid-19 variants
By IPP Bureau - August 17, 2021
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
Suven Life Sciences announces Phase 3 clinical trial of Masupirdine
By IPP Bureau - August 17, 2021
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Lupin receives tentative U.S. FDA approval for Brivaracetam tablets
By IPP Bureau - August 17, 2021
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
.jpg "India-Sweden Healthcare innovation challenge launched")
India-Sweden Healthcare innovation challenge launched
By IPP Bureau - August 17, 2021
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
One more lab approved for batch-testing and release of Covid-19 vaccines
By IPP Bureau - August 17, 2021
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
Centre allocates Rs 267.35 crores to Kerala for Covid response
By IPP Bureau - August 17, 2021
Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine
SCHOTT and Serum Institute announce JV for pharma packaging
By IPP Bureau - August 17, 2021
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Indian pharma’s vaccine opportunity at US $ 10-11 billion
By IPP Bureau - August 17, 2021
Domestic market and developing countries will need doses of Indian vaccines
Zydus Cadila receives tentative approval for cancer drug
By IPP Bureau - August 17, 2021
Lenalidomide is used to treat cancer and also some anaemia disorders
Caplin Point Lab's subsidiary receives nod from Brazil's ANVISA for sterile injectable manufacturing site
By IPP Bureau - August 17, 2021
The approval allows it to market its products in the country
.jpg "Fortis Healthcare PAT at Rs 263.55 cr in Q1FY22")
Fortis Healthcare PAT at Rs 263.55 cr in Q1FY22
By IPP Bureau - August 16, 2021
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
Researchers develop remote ultrasound imaging using robotic technology
By IPP Bureau - August 16, 2021
The project is a collaboration between IIT Delhi and AIIMS
Aster DM Heathcare plans India expansion
By IPP Bureau - August 16, 2021
Investment of Rs 235 crores to add 411 beds in the next 18 months
IOL Chemicals and Pharma commissions Unit-10 for Rs 28.69 crores
By IPP Bureau - August 16, 2021
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
